Clinical-stage Biotechnology Company Announces Patent Licensing Agreement With Research Firm
Clearmind Medicine’s recent announcement marks the beginning of a pivotal phase in its development trajectory.
Welcome to a new era in the treatment of post-traumatic stress disorder (PTSD) and other mental health conditions, Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0), a clinical-stage biotech innovator at the forefront of psychedelic-derived therapeutic development, has announced a landmark exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This collaboration is set to bring to light the innovative work of Professors Rami Yaka, Ahmed Masaewa, and Avi Priel, whose pioneering compounds promise to revolutionize the way we approach PTSD treatment on a global scale. $Clearmind Medicine(CMND.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
